Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.

Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies.

Objectives: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study.

Azelainsäure 20 % Creme: Auswirkung auf Lebensqualität und Krankheitsaktivität bei erwachsenen Patientinnen mit Acne vulgaris.

Hintergrund: Zur Wirksamkeit von Aknetherapien und deren Auswirkungen auf die Lebensqualität erwachsener Patienten liegen kaum Daten vor. ZIEL: Erhebung der Wirkung von Azelainsäure 20 % Creme (Skinoren ) auf Akne-Schweregrad und krankheitsbedingte Lebensqualität.

Patienten Und Methodik: Nichtinterventionelle Studie bei erwachsenen Patientinnen mit leichter bis mittelschwerer Akne.

Azelaic acid 20 % cream: effects on quality of life and disease severity in adult female acne patients.

Background: Data on the efficacy of acne treatments and their impact on quality of life (QoL) in adult patients is sketchy.

Objective: Assessment of the efficacy of azelaic acid 20 % cream (Skinoren ) on acne severity and disease-related QoL.

Patients And Methods: Noninterventional study in adult female patients with mild to moderate acne.